How severe is CVE-2020-10627?

CVE-2020-10627 has a CVSS 3.x base score of 7.3, rated high severity. It is exploitable over local access with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is low, integrity high, and availability low.

Is CVE-2020-10627 being actively exploited?

It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (38th percentile), an estimate of the probability of exploitation in the next 30 days.

What products are affected by CVE-2020-10627?

CVE-2020-10627 affects Insulet Omnipod Insulin Management System Firmware. See the affected-products list for the exact vulnerable versions.

How do I fix CVE-2020-10627?

Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.

When was CVE-2020-10627 published?

CVE-2020-10627 was published on 2021-12-01 and last updated on 2026-06-17.

CVE-2020-10627

CVE-2020-10627 is a high-severity vulnerability in Insulet Omnipod Insulin Management System Firmware with a CVSS 3.x base score of 7.3. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-284.

Key facts

Severity: High (CVSS 3.x base score 7.3)
CVSS v2: 4.8
EPSS exploit prediction: 0% (38th percentile)
Actively exploited: Not listed in CISA KEV
Weakness: CWE-284
Affected product: Insulet Omnipod Insulin Management System Firmware
Published: 2021-12-01
Last modified: 2026-06-17

Description

Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.

Frequently asked questions

What is CVE-2020-10627?: Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.
How severe is CVE-2020-10627?: CVE-2020-10627 has a CVSS 3.x base score of 7.3, rated high severity. It is exploitable over local access with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is low, integrity high, and availability low.
Is CVE-2020-10627 being actively exploited?: It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (38th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2020-10627?: CVE-2020-10627 affects Insulet Omnipod Insulin Management System Firmware. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2020-10627?: Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2020-10627 published?: CVE-2020-10627 was published on 2021-12-01 and last updated on 2026-06-17.

References

Affected products (1)

cpe:2.3:o:insulet:omnipod_insulin_management_system_firmware:-:*:*:*:*:*:*:*

Other CWE-284 (Improper Access Control) vulnerabilities

CVE-2026-50746 — Critical (CVSS 10.0): A malicious actor with access to the network could exploit an Improper Access Control vulnerability found in UniFi…
CVE-2026-46978 — Critical (CVSS 10.0): Vulnerability in the Oracle Solaris product of Oracle Systems (component: Remote Administration Daemon). The…
CVE-2026-35308 — Critical (CVSS 10.0): Vulnerability in the Oracle Coherence product of Oracle Fusion Middleware (component: Centralized Third Party Jars).…
CVE-2026-35307 — Critical (CVSS 10.0): Vulnerability in the Oracle Coherence product of Oracle Fusion Middleware (component: Core). Supported versions that…
CVE-2026-46695 — Critical (CVSS 10.0): Boxlite is a sandbox service that allows users to create lightweight virtual machines (Boxes) and launch OCI containers…
CVE-2026-46840 — Critical (CVSS 10.0): Vulnerability in Oracle REST Data Services (component: Backend-as-a-Service). Supported versions that are affected are…

Browse all CWE-284 (Improper Access Control) vulnerabilities →